TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
NEW YORK, Dec. 07, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc. (NASDAQ:IPXL) securities between February 25, 2014 and November 3, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/impax-laboratories. There is no cost or obligation to you.
According to the complaint, during the Class Period the Company made false and/or misleading statements and/or failed to disclose that: (a) Impax was engaged in conduct that would cause the antitrust division of the U.S. Department of Justice and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (b) the DOJ investigation and the underlying conduct was likely to result in criminal charges against Impax, and possibly its officers and directors, for collusion of generic drug pricing; (c) Impax lacked effective internal controls over financial reporting; and (d) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Impax you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/impax-laboratories.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
